OP White Papers - random

1. Redefining Biomanufacturing For Personalized Cancer Vaccines 4/24/2026

   Personalized cancer vaccines need fast, flexible manufacturing. Cell‑free synthetic DNA enables rapid, small‑batch mRNA production, supporting individualized therapies beyond plasmid‑based limits.

2. How To Effectively Manage Local Affiliate Pharmacovigilance Outsourcing 5/12/2026

   Managing PV across dozens of markets strains even experienced safety teams. Learn about a framework that helps you maintain compliance, reduce risk, and scale confidently into new markets.

3. Using Plant Peptones To Boost Plasmid Yield And Induction 2/12/2026

   Uncover how Nu‑Tek’s plant-based peptones support E. coli growth, plasmid yield, and controlled induction, offering a sustainable, animal-free alternative for biopharmaceutical cell culture.

4. mRNA Therapeutic Development Through Enhanced IVT Capping Efficiency 4/16/2025

   See how Codex HiCap RNA Polymerase supports the production of high-performance synthetic mRNA, paving the way for next-generation mRNA therapies.

5. Biocapacitance Measurement: A PAT Tool For Biomass Measurement In An Upstream Process 3/20/2026

   Leverage process analytical technologies (PAT) to gain real-time insight into product quality, strengthen control strategies, and build more efficient, scalable manufacturing processes for future success.

6. How To Avoid Sticking And Picking In The Tableting Industry 9/23/2024

   Review strategies to mitigate sticking and picking risks in the tablet industry, and learn how you can foster improved tablet production processes, ensuring higher quality and consistency.

7. Building Late-Stage Efficiency Into Biologics Development 8/6/2026

   Building late-stage efficiency early in biologics development prevents scale-up delays. Flexible platforms and risk-based validation streamline technology transfer and lower production costs.

8. A Faster Path To Genomic Medicine Feasibility 3/17/2026

   Life Edit accelerates genomic medicine by comparing five editing modalities, engineering new enzymes, and rapidly pinpointing optimal strategies that boost feasibility, cut risk, and speed clinical progress.

9. Synthetic DNA As An Alternative For Scalable Viral Vector Production 3/30/2026

   Enzymatically synthesized DNA is assessed as a plasmid alternative, showing comparable viral vector yield, quality, and purification, while improving scalability and regulatory flexibility.

10. The Importance Of Quality In Raw Material Selection 1/16/2025

    Learn how to select high-quality raw materials for cell-based manufacturing in this exploration of the criticality of raw materials, from preclinical development to commercialization.